Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. Promedior is … Continue reading →

New Haven, Conn. – A Yale-led study has identified a gene expression profile that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF). The study appears in Science Translational … Continue reading →

By Cindy Krischer Goodman cindykgoodman@gmail.com Jose Guzman began gasping for breath while using his treadmill on the lowest setting and knew something was wrong. His search for answers led him to the diagnosis of a rare lung disease with no … Continue reading →

Abstract During the past decade important progress has been made regarding the pathogenesis of idiopathic pulmonary fibrosis (IPF), which is the most devastating form of idiopathic interstitial pneumonia with a median survival of 3 years. The knowledge gained has been … Continue reading →

Israel researchers uncover secrets of how a certain white blood cell can flip from being a ‘good guy’ to a ‘bad guy’ in diseases with no current cure. Doctoral student Danielle Karo-Atar studying macrophages at Tel Aviv University. A type … Continue reading →

HAYWARD, Calif.–(BUSINESS WIRE)– The National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), awarded Aradigm Corporation (ARDM) a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux with aspirations into … Continue reading →

Oxidative stress (imbalance between oxidants and antioxidants) is part of the story of how COPD causes symptoms of cough and shortness of breath. Cigarette smoke is the main source of oxidation damage in the lungs leading to COPD, but even … Continue reading →